sees fy adjusted earnings per share $2.07 to $2,27.
sees q3 adjusted earnings per share $0.50 to $00.56 excluding items.
q3 adjusted earnings per share $0.64 excluding items.
sees fy sales $5.2 billion to $54.4 billion.
sees fy 2021 tmtt sales $80 million to $100 million.
q2 sales $1.4 billion versus refinitiv ibes estimate of $1 billion.
q2 global sales $902 million versus refinitiv ibes estimate of $819.7 million.
q2 adjusted gross profit margin of 75.9% versus 74.4%.
qtrly total sales grew 49% year-over-year.
qtrly sapien valve usage was more than 30,000 patients.
q2 sales $215 million versus refinitiv ibes estimate of $218.6 million.
sees underlying tavr sales growth of about 20% in 2021 versus previous expectation of 15% to 20%.
sees fy 2021 adjusted gross profit margin to be between 76% and 77%.
q2 sales rose 11 percent to $11.2 billion.
q2 sales $237 million versus refinitiv ibes estimate of $243.4 million.
qtrly global sales of $22 million, driven by continued adoption of pascal platform, as activated more centers across europe.
